Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860196 | 0.99 | ALDH1A1 (0.44) | SMN1; SMN2KDM4ERECQLALDH1A1LMNA | |
| SCHEMBL5759747 | 0.91 | KMT2A (0.37) | KDM4EALDH1A1LMNAHPGDCYP3A4 | |
| SCHEMBL5762299 | 0.86 | HDAC4 (0.46) | SMN1; SMN2ALDH1A1LMNATSHRMAPK1 | |
| SCHEMBL5759681 | 0.86 | MAOB (0.53) | SMN1; SMN2ALDH1A1HTTMAPT | |
| SCHEMBL5762163 | 0.83 | SCN9A (0.38) | KDM4EALDH1A1LMNAHPGDCYP3A4 | |
| SCHEMBL5761768 | 0.82 | KCNA5 (0.53) | KDM4EALDH1A1LMNAHPGDCYP3A4 | |
| SCHEMBL5762790 | 0.82 | ALDH1A1 (0.44) | SMN1; SMN2KDM4EALDH1A1LMNATSHR | |
| SCHEMBL5757048 | 0.81 | MAPT (0.46) | SMN1; SMN2KDM4EALDH1A1LMNATSHR | |
| SCHEMBL5761750 | 0.80 | KDM4E (0.46) | KDM4EALDH1A1LMNAHPGDCYP3A4 | |
| SCHEMBL5760140 | 0.80 | MCL1 (0.47) | KDM4EALDH1A1HPGDGAAAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098340-B2 | Quinoline/chromene derivatives as androgen antagonist | WARNER LAMBERT COMPANY LLC (US) | 2006-08-29 | — | — | US | claimed |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | DU DANIEL Y (US) | 2005-06-23 | — | — | US | claimed |
| US-7098340-B2 | Quinoline/chromene derivatives as androgen antagonist | WARNER LAMBERT COMPANY LLC (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050137228-A1 | Benzyl sulfonamide derivatives | DU DANIEL Y (US) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137228-A1 | Benzyl sulfonamide derivatives | AR, SHBG, BRDT | SMN1; SMN2 3908/4885KDM4E 870/4885RECQL 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.